PMID- 11576375
OWN - NLM
STAT- MEDLINE
DCOM- 20020103
LR  - 20191210
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 60
IP  - 4
DP  - 2001 Oct
TI  - Filtration of native and glycated beta2-microglobulin by charged and neutral 
      dialysis membranes.
PG  - 1571-7
AB  - BACKGROUND: It has been postulated that protein glycation and formation of 
      advanced glycation end products (AGE) are among toxic factors in chronic uremia, 
      whether the renal disease is of diabetic or nondiabetic origin. In this setting, 
      AGE-modified beta2-microglobulin (beta2m) may favor dialysis beta2m-related 
      dialysis amyloidosis. Consequently, efficient removal of modified beta2m by 
      highly permeable dialysis membranes is as important as removal of native beta2m 
      to postpone the development of dialysis amyloidosis. METHODS: To define the role 
      of dialysis membrane surface electronegativity on plasma protein transfer, an in 
      vitro model was used to test the interactions of native and glycated beta2m with 
      various highly permeable dialysis membranes. An experimental circuit with 
      minidialyzers was used. The neutral high-flux polysulfone membrane (PS), the 
      electronegative polymethylmetacrylate membrane (PMMA), the electronegative AN69 
      membrane and a modified AN69 membrane, the surface of which was neutralized with 
      polyethyleneimine (AN69-PEI), were tested using both native beta2m and the more 
      acidic glycated beta2m. Protein mass transfer and binding to the membrane were 
      measured. RESULTS: Mass transfer of glycated beta2m was significantly decreased 
      through all membranes tested when compared with native beta2m. This result was 
      due to the increased molecular weight of beta2m, which became less permeable to 
      porous membranes, whereas adsorption of both native and glycated beta2m to 
      membranes, due to ionic interactions, decreased similarly with AN69 and AN69-PEI, 
      but remained unchanged with PS and PMMA. Moreover, surface neutralization of AN69 
      membrane did not alter its core binding capacity, since beta2m absorption 
      accounted for 98 and 97% and glycated beta2m for 83.7 and 81.4% of the protein 
      removed with AN69 and AN69-PEI, respectively. CONCLUSION: Clearance of glycated 
      beta2m through highly permeable neutral and negatively charged membranes was 
      lower than that of native beta2m, reflecting a decreased sieving coefficient for 
      the neoformed higher molecular weight and conformationally altered molecule. The 
      binding capacity of the neutral PS was roughly half that of the charged 
      membranes. Neutralizing surface electronegativity of the AN69 membrane with PEI 
      did not alter its binding capacity. These results suggest that it would be useful 
      for dialysis protocols to include comparative studies of both serum native and 
      modified beta2m in order to prevent beta2m-amyloidosis.
FAU - Randoux, C
AU  - Randoux C
AD  - Service de Nephrologie and Laboratoire de Biochimie, Centre Hospitalier et 
      Universitaire, Reims, France.
FAU - Gillery, P
AU  - Gillery P
FAU - Georges, N
AU  - Georges N
FAU - Lavaud, S
AU  - Lavaud S
FAU - Chanard, J
AU  - Chanard J
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 0 (Acrylic Resins)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Membranes, Artificial)
RN  - 0 (Polymers)
RN  - 0 (Sulfones)
RN  - 0 (beta 2-Microglobulin)
RN  - 25135-51-7 (polysulfone P 1700)
RN  - 60650-36-4 (AN-69)
RN  - 9011-14-7 (Polymethyl Methacrylate)
RN  - MP1U0D42PE (Acrylonitrile)
SB  - IM
MH  - Acrylic Resins
MH  - Acrylonitrile/*analogs & derivatives
MH  - Amyloidosis/prevention & control
MH  - Biocompatible Materials
MH  - Blood Component Removal/*instrumentation/*methods
MH  - Electricity
MH  - Glycosylation
MH  - Hemofiltration/*instrumentation/*methods
MH  - Humans
MH  - Kinetics
MH  - *Membranes, Artificial
MH  - Polymers
MH  - Polymethyl Methacrylate
MH  - Renal Replacement Therapy/*instrumentation
MH  - Sulfones
MH  - beta 2-Microglobulin/*isolation & purification/metabolism
EDAT- 2001/09/29 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/09/29 10:00
PHST- 2001/09/29 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/09/29 10:00 [entrez]
AID - S0085-2538(15)48029-9 [pii]
AID - 10.1046/j.1523-1755.2001.00970.x [doi]
PST - ppublish
SO  - Kidney Int. 2001 Oct;60(4):1571-7. doi: 10.1046/j.1523-1755.2001.00970.x.